Beer Kenneth R
Palm beach Esthetic Center, West Palm Beach, FL 33401, USA.
Dermatol Surg. 2006 Feb;32(2):184-97. doi: 10.1111/j.1524-4725.2006.32036.x.
Several nonprescription products purport similar or better outcomes than botulinum toxin type A (Botox Cosmetic, Allergan Inc., Irvine, CA, USA) for treating wrinkles, but these have not been documented in comparative clinical trials. Patients spend millions of dollars annually on the topical products, yet there are, to date, no data to support any of the claims made.
To compare the efficacy and safety of botulinum toxin type A with placebo and three topical products in treating moderate-to-severe glabellar lines.
This single-center, randomized, investigator-blinded, parallel study of 77 female subjects comprised five treatment groups: botulinum toxin type A, placebo injection, StriVectin-SD (Klein-Becker USA, Salt Lake City, UT, USA), DDF Wrinkle Relax (Doctor's Dermatologic Formula, HDS Cosmetics, Inc., Yonkers, NY, USA), and HydroDerm (Hydroderm, Beverly Hills, CA, USA). Baseline and follow-up visits (weeks 4, 8, and 12) assessed safety and key efficacy measures: blinded investigator assessment of glabellar line severity on the Facial Wrinkle Scale (FWS), subjects' global assessment of overall change in appearance, subject ratings of glabellar-related self-perception pre- and post-treatment, and satisfaction with treatment.
Botulinum toxin type A treatment consistently resulted in statistically significant reductions in wrinkle severity on the FWS than any comparator (p<.001). Statistically significant improvements were similarly observed for subject-reported outcomes and satisfaction with botulinum toxin type A treatment, whereas treatment with any of the three topical creams did not result in a significant difference from placebo. Three adverse events occurred in three subjects who received StriVectin-SD.
Botulinum toxin type A provided significantly greater efficacy and patient satisfaction in the treatment of glabellar frown lines than StriVectin-SD, Wrinkle Relax, and HydroDerm, and in the objective measurements used, none of the topical preparations were better than botulinum toxin.
几种非处方产品声称在治疗皱纹方面能取得与A型肉毒毒素(保妥适,美国加利福尼亚州欧文市艾尔建公司)相似或更好的效果,但这些尚未在比较性临床试验中得到证实。患者每年在这些外用产品上花费数百万美元,但迄今为止,没有数据支持任何相关宣称。
比较A型肉毒毒素与安慰剂及三种外用产品治疗中重度眉间纹的疗效和安全性。
这项针对77名女性受试者的单中心、随机、研究者盲法、平行研究分为五个治疗组:A型肉毒毒素组、安慰剂注射组、斯佳唯婷SD(美国犹他州盐湖城克莱因 - 贝克尔公司)、DDF抗皱舒缓精华液(美国纽约州扬克斯市医生皮肤配方HDS化妆品公司)和水得美(美国加利福尼亚州比佛利山庄水得美公司)。基线和随访(第4、8和12周)评估安全性和关键疗效指标:研究者采用面部皱纹量表(FWS)对眉间纹严重程度进行盲法评估、受试者对外观整体变化的总体评估、受试者治疗前后眉间相关自我认知评分以及对治疗的满意度。
与任何对照产品相比,A型肉毒毒素治疗始终使FWS上的皱纹严重程度在统计学上显著降低(p<0.001)。在受试者报告的结果和对A型肉毒毒素治疗的满意度方面也观察到类似的统计学显著改善,而三种外用乳膏中的任何一种治疗与安慰剂相比均未产生显著差异。三名接受斯佳唯婷SD治疗的受试者发生了三起不良事件。
在治疗眉间皱眉纹方面,A型肉毒毒素比斯佳唯婷SD、抗皱舒缓精华液和水得美具有显著更高的疗效和患者满意度,并且在所使用的客观测量中,没有一种外用制剂比A型肉毒毒素更好。